Valuation: PYC Therapeutics Limited

Market Cap 2.07B 1.48B 1.27B 1.19B 1.09B 2.04B 142B 14.02B 5.47B 71.16B 5.56B 5.44B 235B P/E 2026 *
-29.1x
P/E 2027 * -22.8x
Enterprise Value 1.4B 1B 860M 805M 737M 1.38B 96.09B 9.51B 3.71B 48.27B 3.77B 3.69B 160B EV / Sales 2026 *
382x
EV / Sales 2027 * -
Free-Float
70.64%
Yield 2026 *
-
Yield 2027 * -
1 day+1.45%
1 week-1.41%
Current month+23.53%
1 month+26.51%
3 months+56.72%
6 months+40.94%
Current year+26.89%
1 week 2.05
Extreme 2.05
2.22
1 month 1.62
Extreme 1.62
2.23
Current year 1.04
Extreme 1.045
2.23
1 year 0.85
Extreme 0.847
2.23
3 years 0.52
Extreme 0.52
2.23
5 years 0.5
Extreme 0.5
2.23
10 years 0.15
Extreme 0.15
2.23
Manager TitleAgeSince
Chief Executive Officer 42 19/08/2020
Director of Finance/CFO 47 07/07/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 30/11/2018
Director/Board Member - 22/09/2025
Chairman 66 18/11/2025
Date Insider Type Main position Quantity % Market Cap.
13/8/26 Free

Chief Executive Officer

4,598,662 0.4676%
13/8/26 Free

Chief Executive Officer

10,477,965 1.0654%
13/8/26 Free

Chief Executive Officer

7,706,503 0.7836%
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%-1.41%+61.54%+262.07% 1.46B
-0.83%+4.03%+2.86%+23.39% 51.61B
-1.13%-2.54%+479.25%+549.34% 44.89B
-0.03%+8.35%+39.03%+21.29% 42.77B
-2.05%+1.11%+18.76%+84.29% 42.58B
-0.93%-4.33%+16.18%+55.82% 31.82B
-0.34%+4.24%+33.34%+146.19% 17.33B
-1.25%+0.46% - - 16.63B
+0.38%+4.43%+9.53%+30.58% 14.76B
-0.11%+3.43%+80.65%+49.26% 14.09B
Average -0.48%+3.66%+82.35%+135.81% 27.79B
Weighted average by Cap. -0.82%+4.67%+101.76%+138.56%

Financials

2026 *2027 *
Net sales 3.67M 2.63M 2.25M 2.11M 1.93M 3.62M 251M 24.89M 9.71M 126M 9.87M 9.65M 418M -
Net income -57.43M -41.17M -35.26M -33M -30.2M -56.68M -3.94B -390M -152M -1.98B -155M -151M -6.54B -85.75M -61.47M -52.65M -49.26M -45.1M -84.63M -5.88B -582M -227M -2.95B -231M -226M -9.77B
Net Debt -664M -476M -408M -382M -349M -656M -45.56B -4.51B -1.76B -22.89B -1.79B -1.75B -75.69B -579M -415M -355M -333M -304M -571M -39.69B -3.93B -1.53B -19.94B -1.56B -1.52B -65.95B
Logo PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Employees
5
Date Price Change Volume
24/08/26 $2.100 +1.45% 2,019,395
21/08/26 $2.070 -5.91% 2,827,588
20/08/26 $2.200 +2.33% 1,520,843
19/08/26 $2.150 +0.47% 1,680,719
18/08/26 $2.140 +0.47% 1,855,912
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.070AUD
Average target price
3.752AUD
Spread / Average Target
+81.26%

Quarterly revenue - Rate of surprise